What the name means
“Wolverine” is not a peptide. It is a marketing name — a nod to the comic-book character who heals instantly — that grey-market vendors attach to a vial containing two research peptides, BPC-157 and TB-500, usually lyophilised together. There is no standard ratio: one seller's “Wolverine” is 5 mg of each, another's is 10 mg and 5 mg, and the label is the only source of that information. The two peptides have separate profiles on this site; this guide distinguishes the marketed blend from its individual components.
| Component | What it is | Human evidence | Regulatory status |
|---|---|---|---|
| BPC-157 | 15-residue synthetic fragment related to a gastric protein; studied in rodent injury models | No randomized human efficacy trial in cited sources | Canadian product authorization requires checking; see Health Canada notice |
| TB-500 | Synthetic 7-residue fragment (Ac-LKKTETQ) of thymosin β4's actin-binding region | None for the fragment itself; full-length thymosin β4 has been in small trials (e.g., dry eye) | See product-specific regulator records; separate sports rules may apply |
BPC-157: what has and has not been shown
BPC-157 is a 15-amino-acid synthetic peptide (GEPPPGKPADDAGLV) derived from a sequence in human gastric juice. Its literature is large but almost entirely from one research group and almost entirely in rats: tendon, muscle, ligament and gut injury models, with reported acceleration of healing. Mechanistic proposals include effects on nitric oxide signalling, VEGF-driven angiogenesis and growth-factor receptor expression. In humans there is no completed randomised trial showing benefit for any injury; the published human data amount to limited uncontrolled human reports. The BPC-157 profile lists the primary references.
TB-500: a fragment of a real hormone
Thymosin β4 (Tβ4) is a 43-amino-acid protein that sequesters actin monomers and is involved in cell migration and tissue repair; it has been studied in humans for corneal healing, dry eye and cardiac repair, mostly in small trials with mixed results. “TB-500” as sold is not Tβ4 — it is a 7-residue synthetic fragment (acetyl-LKKTETQ) corresponding to Tβ4's actin-binding motif. The fragment has no human trials at all, and the assumption that it reproduces the full protein's biology is exactly that: an assumption. The TB-500 profile separates the two.
What the combination study found
Biçer et al. (2026) studied BPC-157, TB-500 and their combination in 32 rats after Achilles tendon repair. The combination did not provide added benefit over either agent alone. This is an exploratory animal result, not proof that a marketed blend works in humans. The cited sources do not establish a standardized formulation, a human benefit or the stability of mixed commercial vials. Claims of synergy require their own evidence.
Legal and safety status
Health Canada has warned about unauthorized injectable peptides sold online, including products described with these ingredient names. Its warning concerns Canadian products and does not establish every jurisdiction's approval status. Check the particular regulator, product and indication. A research label does not demonstrate safety, quality or authorization, and the sources here do not establish human safety of a marketed blend.
Reading the claims responsibly
The sources cited here do not establish authorization, human efficacy or safety for the marketed blend. “Research use only” labelling does not change that. This page explains what the name refers to; it is not guidance on obtaining or using any product.
Sources and what they cover
These primary studies, official records and standards cover the topics linked below. The scope notes distinguish laboratory findings, human trials and regulatory records. This is a selected bibliography, not a systematic review or verification of every sentence; absence of a study here does not prove that no study exists.
- Cerovecki et al. (2010) — BPC-157 and ligament healing in rats
Rat injury model; cannot establish benefit or a safe route of administration in humans.
Relevant sections: BPC-157: what has and has not been shown
- Rahaman et al. (2024) — TB-500 metabolites, analytical testing and in-vitro wound assays
In-vitro and rat work on TB-500. Results for full-length thymosin beta-4 are a separate evidence base.
Relevant sections: TB-500: a fragment of a real hormone
- Biçer et al. (2026) — BPC-157, TB-500 and their combination in rat Achilles tendon repair
32-rat experiment with the authors' TB-500 material; its sequence was not characterized. No added combination benefit; not human evidence.
Relevant sections: What the combination study found · Reading the claims responsibly
- Health Canada (2026) — unauthorized injectable peptides bought online
Canadian safety and authorization notice for the products described. It does not establish approval status in every country.
Relevant sections: Legal and safety status
FAQ
What is the Wolverine peptide?+
A vendor nickname for a vial combining BPC-157 and TB-500, two unapproved research peptides. It is not a single peptide, and the ratio varies by seller.
Is the Wolverine peptide FDA-approved?+
No FDA authorization for the marketed blend is documented in the sources cited here. Ingredient names or a research label do not establish product approval.
Has the BPC-157 + TB-500 combination been studied?+
Yes, an exploratory 2026 rat tendon-repair study tested both together and found no added benefit over either agent alone. It does not establish effectiveness or safety of a marketed blend in humans.
What is the difference between TB-500 and thymosin β4?+
Thymosin β4 is a 43-residue human protein with small clinical trials. TB-500 is a synthetic 7-residue fragment of it with no human data.
Is the Wolverine peptide the same as GLOW?+
No. GLOW adds GHK-Cu to the same two peptides; KLOW adds KPV as well. Each has its own page.
Related peptide profiles
More guides
- What Is the “GLOW” Peptide? GHK-Cu + BPC-157 + TB-500, Explained From the Evidence
- What Is the “KLOW” Peptide? KPV + GHK-Cu + BPC-157 + TB-500, Component by Component
- BPC-157 vs TB-500: Differences, Research Context & Comparison
- Peptide Safety and Risks: A Balanced Educational Overview
- What Are Research Peptides? A Clear Educational Guide